Multiple antigen specific cell therapy (MASCT)

多抗原自体免疫细胞

Report date: 2025/06/23 17:27:15

Base Information

Drug NameMultiple antigen specific cell therapy (MASCT)
Drug Alias NameMASCT多抗原自体免疫细胞注射液Neo-MASCTMultiple target antigen stimulating cell therapy-IMultiple-antigen specific cell therapy-I +[9] 
ClassificationVaccines > Development/production technology > Dendritic cell vaccineCell and gene therapy > Cell therapy > Immune system cell therapy > Dendritic cell therapy > Dendritic cell vaccine
Mechanisms of ActionImmunostimulantsImmunologic cytotoxicityCytotoxic T lymphocytes stimulants
TargetsNot applicable
Therapy Area/IndicationsSolid tumoursLiver DiseasesCarcinoma, Non-Small-Cell Lung +[17] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesHengrui Yuanzheng (Shanghai) Biotechnology Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesHRYZ Biotech Co LtdHengrui Yuanzheng (Shenzhen) Biological Technology Co LtdHengrui Yuanzheng (Shanghai) Biotechnology Co Ltd
Inactive CompaniesSun Yat-Sen University
Active IndicationsSolid tumoursCarcinoma, Transitional CellHemangiosarcoma +[12] 
Inactive IndicationsLiver DiseasesCarcinoma, Non-Small-Cell LungLiver Neoplasms +[5] 

Other Information

ATC CodeN/A
Related LinksN/A